IP Library Granted Patent US 11,091,743
Granted Patent B2
US 11,091,743 · App. 16/323,756 · Granted Aug 17, 2021

UDP-dependent glycosyltransferase for high efficiency production of rebaudiosides

Inventors: Lishan Zhao (Emeryville, CA); Wenzong Li (Emeryville, CA); Gale Wichmann (Berkeley, CA); Aditi Khankhoje (Emeryville, CA); Chantal Garcia De Gonzalo (Richmond, CA); Tina Mahatdejkul-Meadows (Milpitas, CA); Shaina Jackson (Oakland, CA); Michael Leavell (Richmond, CA); Darren Platt (San Francisco, CA)
Assignee: AMYRIS, INC.
C12N9/1051A23L2/60A23L27/36C12N15/52C12N15/81C12P19/18C12P19/56C12Y204/01017A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,091,743
App. No.
16/323,756
Granted
Aug 17, 2021
Kind
B2
Abstract

Provided herein are compositions and methods for improved production of steviol glycosides in a host cell. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding a Setaria italica UDP-glycosyltransferase 40087 or its variant UDP-glycosyltransferase. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding a UDP-glycosyltransferase sr.UGT_9252778, Bd_uGT10850, and/or Ob_UGT91B_1 like. In some embodiments, the host cell further comprises one or more heterologous nucleotide sequence encoding further enzymes of a pathway capable of producing steviol glycosides in the host cell. The compositions and methods described herein provide an efficient route for the heterologous production of steviol glycosides, including but not limited to, rebaudioside D and rebaudioside M.

Claims (43)

1. A genetically modified yeast host cell comprising a heterologous nucleic acid encoding a UDP-glycosyltransferase, comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 1, wherein the genetically modified host cell is capable of converting rebaudioside A (RebA) to rebaudioside D (RebD) at an efficiency of greater than 90%.

2. The genetically modified host cell of claim 1 , wherein the UDP-glycosyltransferase comprises an amino acid sequence having the sequence of SEQ ID NO:1.

3. The genetically modified host cell of claim 1 , wherein the UDP-glycosyltransferase is capable of beta 1,2 glycosylation of the C2′ position of the 19-0 glucose of a steviol glycoside.

4. The genetically modified host cell of claim 1 , wherein the UDP-glycosyltransferase is encoded by a heterologous nucleic acid, wherein the heterologous nucleic acid comprises a nucleotide sequence having at least 80% sequence identity to SEQ ID NO:13.

5. The genetically modified host cell of claim 1 , wherein the UDP-glycosyltransferase is encoded by a heterologous nucleic acid having the sequence of SEQ ID NO:13.

6. The genetically modified host cell of claim 1 , that is capable of converting RebA to RebD at an efficiency of greater than 90% and wherein the UDP-glycosyltransferase comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO:l.

7. The genetically modified host cell of claim 1 , wherein the UDP-glycosyltransferase comprises the amino acid sequence SEQ ID NO:24.

8. The genetically modified host cell of claim 1 , wherein the UDP-glycosyltransferase comprises an amino acid sequence having at least 92% sequence identity to SEQ ID NO:l.

9. The genetically modified host cell of claim 1 that is capable of producing RebD.

10. The genetically modified host cell of claim 1 that is capable of producing rebaudioside M (RebM).

11. The genetically modified host cell of claim 1 that is capable of producing at RebM and rebaudioside M2 (RebM2) at a ratio of at least 10:1, 100:1, or 1000:1.

12. The genetically modified host cell of claim 1 , wherein the genetically modified host cell produces an undetectable level of RebM2.

13. The genetically modified host cell of claim 1 , wherein the genetically modified host cell is capable of converting stevioside to rebaudioside E (RebE).

14. The genetically modified host cell of claim 1 , wherein the genetically modified host cell further comprises one or more heterologous nucleic acids encoding one or more enzymes of a pathway for making steviol.

15. The genetically modified host cell of claim 1 , wherein the genetically modified host cell further comprises one or more heterologous nucleic acids encoding one or more enzymes of a pathway for making a steviol glycoside.

16. The genetically modified host cell of claim 1 , wherein the genetically modified host cell further comprises one or more heterologous nucleic acids encoding one or more enzymes of a pathway for making a RebA.

17. The genetically modified host cell of claim 1 , wherein the genetically modified host cell further comprises one or more heterologous nucleic acids encoding one or more enzymes of a pathway for making RebM.

18. The genetically modified host cell of claim 1 , wherein the genetically modified host cell further comprises one or more heterologous nucleic acids encoding one or more enzymes of a pathway for making RebE.

19. The genetically modified host cell of claim 14 , wherein the one or more enzymes of the pathway comprise a geranylgeranyl diphosphate synthase.

20. The genetically modified host cell of claim 14 , wherein the one or more enzymes of the pathway comprise a copalyl diphosphate synthase.

21. The genetically modified host cell of claim 14 , wherein the one or more enzymes of the pathway comprise an ent-kaurene synthase.

22. The genetically modified host cell of claim 14 , wherein the one or more enzymes of the pathway comprise a kaurene oxidase.

23. The genetically modified host cell of claim 14 , wherein the one or more enzymes of the pathway comprise a kaurenoic acid hydroxylase.

24. The genetically modified host cell of claim 14 , wherein the one or more enzymes of the pathway comprise a cytochrome P450 reductase.

25. The genetically modified host cell of claim 15 , wherein the one or more enzymes of the pathway comprise a uridine 5′-diphospho glycosyltransferase.

26. The genetically modified host cell of claim 15 , wherein the one or more enzymes of the pathway comprise UGT74G1 (SEQ ID NO: 31), UGT76G1 (SEQ ID NO: 32), UGT85C2 (SEQ ID NO: 33), and UGT91D (SEQ ID NO:7).

27. The genetically modified host cell of claim 15 , wherein the one or more enzymes of the pathway comprise a geranylgeranyl diphosphate synthase, a copalyl diphosphate synthase, a ent-kaurene synthase, a kaurene oxidase, a kaurenoic acid hydroxylase, a cytochrome P450 reductase, UGT74G1 (SEQ ID NO: 31), UGT76G1 (SEQ ID NO: 32), UGT85C2 (SEQ ID NO: 33), and UGT91D (SEQ ID NO:7).

28. The genetically modified host cell of claim 14 , wherein the one or more enzymes of the pathway comprises a bifunctional copalyl diphosphate synthase and kaurene synthase.

29. The genetically modified host cell of claim 27 , wherein the one or more heterologous nucleic acids encoding one or more enzymes of the pathway are under control of a single transcriptional regulator.

30. The genetically modified host cell of claim 27 , wherein the one or more heterologous nucleic acids encoding one or more enzymes of the pathway are under control of multiple heterologous transcriptional regulators.

31. The genetically modified host cell of claim 1 , wherein the yeast is Saccharomyces cerevisiae.

32. A method for producing RebD:

(a) culturing a population of the genetically modified host cells claim 1 in a medium with a carbon source under conditions suitable for making RebD; and

(b) recovering said RebD compound from the medium.

33. A method for producing RebM:

(a) culturing a population of the genetically modified host cells claim 1 in a medium with a carbon source under conditions suitable for making RebM; and

(b) recovering said RebM compound from the medium.

34. The genetically modified host cell of claim 1 , comprising a heterologous nucleic acid encoding a UDP-glycosyltransferase comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO:l.

35. The genetically modified host cell of claim 1 , comprising a heterologous nucleic acid encoding a UDP-glycosyltransferase comprising an amino acid sequence having at least 90%, sequence identity to SEQ ID NO:l.

36. The genetically modified host cell of claim 1 , comprising a heterologous nucleic acid encoding a UDP-glycosyltransferase comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO:l.

37. The genetically modified host cell of claim 1 , wherein the UDP-glycosyltransferase is encoded by a heterologous nucleic acid, wherein the heterologous nucleic acid comprises a nucleotide sequence having at least 85% sequence identity to SEQ ID NO:13.

38. The genetically modified host cell of claim 1 , wherein the UDP-glycosyltransferase is encoded by a heterologous nucleic acid, wherein the heterologous nucleic acid comprises a nucleotide sequence having at least 90% sequence identity to SEQ ID NO:13.

39. The genetically modified host cell of claim 1 , wherein the UDP-glycosyltransferase is encoded by a heterologous nucleic acid, wherein the heterologous nucleic acid comprises a nucleotide sequence having at least 95% sequence identity to SEQ ID NO:13.

Assignments (12)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2025
From: AMYRIS, INC.
To: CORN PRODUCTS DEVELOPMENT, INC.
Reel/Frame 071314/0668 →
RELEASE OF SECURITY INTEREST Recorded May 29, 2025
From: EUAGORE, LLC
To: AMYRIS, INC.
Reel/Frame 071260/0237 →
SECURITY INTEREST Recorded May 24, 2024
From: AMYRIS, INC.
To: EUAGORE, LLC
Reel/Frame 067528/0467 →
SECURITY INTEREST Recorded Aug 17, 2023
From: AMYRIS, INC.; AMYRIS CLEAN BEAUTY, INC.; AMYRIS FUELS, LLC; AB TECHNOLOGIES LLC; APRINNOVA, LLC; AMYRIS-OLINKA, LLC; ONDA BEAUTY INC.; UPLAND 1 LLC; AMYRIS ECO-FAB LLC; CLEAN BEAUTY 4U HOLDINGS, LLC; AMYRIS CLEAN BEAUTY LATAM LTDA; INTERFACES INDUSTRIA E COMERCIA DE COSMETICOS LTDA; AMYRIS BIOTECHNOLOGIA DO BRASIL LTDA; AMYRIS EUROPE TRADING B.V. (NETHERLANDS); AMYRIS BIO PRODCUTS PORTUGAL, UNIPESSOAL, LDA; BEAUTY LABS INTERNATIONAL LIMITED; AMYRIS UK TRADING LIMITED
To: EUAGORE, LLC
Reel/Frame 064619/0778 →
SECURITY INTEREST Recorded Aug 3, 2023
From: AMYRIS CLEAN BEAUTY, INC.; AMYRIS FUELS, LLC; AB TECHNOLOGIES LLC; AMYRIS, INC.
To: MUIRISC, LLC
Reel/Frame 064492/0518 →
RELEASE OF SECURITY INTEREST Recorded Feb 14, 2023
From: NAXYRIS S.A.
To: AMYRIS, INC.
Reel/Frame 062760/0753 →
RELEASE OF SECURITY INTEREST Recorded Feb 14, 2023
From: SCHOTTENFELD OPPORTUNITIES FUND II, L.P.
To: AMYRIS, INC.
Reel/Frame 062760/0818 →
SECURITY INTEREST Recorded Oct 18, 2022
From: AMYRIS, INC.
To: FORIS VENTURES, LLC
Reel/Frame 061703/0499 →
SECURITY INTEREST Recorded Nov 21, 2019
From: AMYRIS, INC.
To: NAXYRIS S.A.
Reel/Frame 051081/0729 →
GRANT OF PATENT SECURITY INTEREST Recorded Nov 20, 2019
From: AMYRIS, INC.
To: SCHOTTENFELD OPPORTUNITIES FUND II, L.P.
Reel/Frame 051072/0310 →
SECURITY INTEREST Recorded Aug 16, 2019
From: AMYRIS, INC.
To: NAXYRIS S.A.
Reel/Frame 050081/0106 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2019
From: ZHAO, LISHAN; LI, WENZONG; WICHMANN, GALE; KHANKHOJE, ADITI; GARCIA DE GONZALO, CHANTAL; MAHATDEJKUL-MEADOWS, TINA; JACKSON, SHAINA; LEAVELL, MICHAEL; PLATT, DARREN
To: AMYRIS, INC.
Reel/Frame 048274/0546 →
Continuity (2)
Provisional Application 62374408 · Aug 12, 2016
Related Publication 20190185826A1 · Jun 20, 2019
Cited By (1)
US 12,371,677